initi coverag
qure resum coverag
messag expand coverag larger cap rare diseas space
recal therapi develop treat rare orphan diseas enjoy sever
benefit includ cooper fda rel lack price pressur vocal
patient advocaci among other combin signific technolog
advanc recent year gene therapi rnai posit space well far
 diseas index ytd vs nbi initi coverag
qure resum coverag opposit
end spectrum also enter nash space resum coverag
recent progress result impress number varieti therapeut
develop pleas see tabl page rate price target estim
see within detail invest these happi holiday
buy rate qure neutral rate
conjunct initi also publish sever background
deck detail
gene therapi generalist seri focus hemophilia
wherein break key issu hemophilia gene therapi provid easili digest
background opinion
earli stage pipelin deep dive dug earlier stage non-
cf pipelin get ahead what next question think start
import
nash primer new hcv liver diseas affect million
peopl us alon took look nash pipelin context
attr pipelin deep dive orphan diseas two recent
approv drug anoth one way
pomp diseas deep drive orphan diseas lot focu
gene therapi perspect
page analyst certif import disclosur
page analyst certif import disclosur
initi coverag share buy rate
price target expect onpattro launch go well given exist pool
identifi patient onpattro profil vs competitor second gen
vutrisiran like solidifi alni competit posit expand
market opportun longer term patient identification/convers
import continu growth dont anticip problem given
highli symptomat diseas state three differ compani vy
patient beyond attr alni broad late stage pipelin proprietari
partner provid sever key clinic catalyst ultim
engin continu top-line growth evolut technolog platform
 deliveri continu feed earli stage pipelin
share mn
factset price
price perform versu nbi
factset price
page analyst certif import disclosur
initi coverag
buy rate
alnylam platform base rnai technolog rna interfer rnai
potent specif natur mechan use mani differ
organ control gene express via posttranscript gene silenc
first discov plant anim bodi use short
double-strand rna sirna recogn bind mrna temporari
copi sequenc dna lead enzymat degrad
mrna prevent translat protein leverag
natur process develop therapeut develop abil
design deliv sirna recogn bind mrna specif
prevent product disease-caus protein
sirna mediat gene regul address gene overexpress
mutat potenti util sever diseas sever compani
develop technolog work area viral infect
cancer genet disord autoimmun diseas cardiovascular disord
focus three key strateg therapeut area star genet
medicin cardio-metabol diseas hepat infecti diseas
alni initi focu therapeut genet diseas associ
gene express liver case exogen nucleic
acid target deliveri repres challeng given poor pharmacokinet
properti ineffici cellular uptak sirna liver rel low-
hang fruit alni initi effort focus deliveri sirna use lipid
nanoparticl lnp lnp attract deliveri vehicl given eas
prepar versatil biocompat biodegrad accumul
record clinic use sirna encapsul lnp deliv
system via iv infus shown potent rapid durabl target
gene silenc gener well toler
onpattro lnp-base rnai therapeut alni first commerci
product first sirna therapeut ever approv onpattro
approv us eu aug treat hereditari transthyretin
amyloidosi hattr rare genet disord diseas caus
misfold accumul ttr protein onpattro target ttr mrna
prevent protein product reduc accumul amyloid deposit
onpattro iv infus deliv everi week trial
treatment onpattro result better outcom measur
polyneuropathi includ muscl strength reflex autonom symptom
walk nutrit statu abil perform activ daili live
onpattro first therapeut treat hattr us
one competit could limit market share albeit grow market
estim hattr patient ww fall within
current label thought diagnos us eu
given see competit tegsedi approv oct
pfe tafamidi compani expect approv hattr-cm patient
double-edg sword voic help rais awareness/increas
diagnosi rate could also limit share within polyneuropathi group
think advantag goe onpattro given lack monitor
requir potenti home infus though weve spoken
doctor dont mind monitor think patient would
page analyst certif import disclosur
prefer tegsedi subq dose current assum limit use
cardiomyopathi subset base label/doc feedback model peak ww
onpattro sale though note increas rate diagnosi big
variabl assum grow
inform attr onpattro competit landscap see attr
background
deliveri could drive signific market share attr broadli
alni next gen therapeut hattr use compani proprietari esc
galnac-conjug deliveri instead lnp target ligand n-
acetylgalactosamin attach sirna facilit receptor-medi
endocytosi data shown ttr knockdown least good onpattro
subq everi dose profil trial helios-a hattr-
pn onpattro current label popul enrol success
model take major onpattro use also take share
competitor also plan evalu drug hattr-cm
wtattr could dramat increas alni address market
alni proprietari pipelin two high probabl asset
develop givosiran lumasiran also util galnac deliveri
therapi target sever debilit rare diseas therapi
approv data program highli encourag
statist signific efficaci vs placebo think studi
rel de-risk efficaci perspect top-line givosiran
data acut hepat porphyria anticip march top-line
lumasiran data primari hyperoxaluria type expect late
expect posit efficaci result safety/toler
coupl issu well keep eye overal think
risk/benefit drug profil favor given sever natur
also elig receiv signific royalti partner
program inclisiran mdco fitusiran sni data
anticip inclisiran target treatment
hypercholesterolemia could provid meaning differenti dose
profil everi subq vs current inhibitor believ
consensu estim inclisiran seem achiev elig
receiv low high-teen royalti hemophilia think fitusiran
hemophilia a/b rel less well posit competit standpoint
assum rel modest uptak elig receiv
royalti info hemophilia market current treatment
competit landscap see hemophilia background
continu innov deliveri front broaden potenti
target organ help keep pipelin stock
forese futur compani continu develop liver target
therapi cemdisiran iga nephropathi aatd
hbv partnership rnai therapeut aln-
hsd nash outsid liver recent advanc deliveri enabl
potenti target broad array diseas like hereditari cerebr
amyloid angiopathi genet valid target diseas like
amyloidosi hypertens
page analyst certif import disclosur
alni posit compani well continu
execut pipelin develop addit launch expect
end cash
alnylam commerci stage biotechnolog compani focus rnai
therapeut highli specif sirna design block product
disease-caus protein cleav silenc target mrna
compani current program make use lipid nanoparticl galnac
conjug approach target liver focus develop
therapeut rare diseas high unmet medic need encompass
genet medicin cardio-metabol hepat infecti diseas along
ailment central nervou system
onpattro patisiran transthyretin amyloidosi attr onpattro
rnai therapeut formul lipid nanoparticl sirna bind
genet conserv sequenc mrna mutant wild type attr
reduc level protein serum tissu therapi
administ via iv infus everi week onpattro
page analyst certif import disclosur
approv us eu august us indic
treatment polyneuropathi adult patient hereditari attr
eu indic treat hattr amyloidosi patient stage
neuropathi includ data apollo exploratori cardiac endpoint
nda submit japan approv anticip
inform attr onpattro competit landscap see
attr background
vutrisiran previous transthyretin amyloidosi attr
like patisiran vutrisiran rnai therapeut target mutant wild type
ttr though make use alni esc-galnac-sirna conjug deliveri
platform could enabl quarterli subcutan dose data
healthi volunt show singl dose result mean maximum
knockdown ttr believ could result similar better
knockdown rel patisiran trial helios-a initi
decemb evalu dose vutrisiran administ
subcutan everi month hattr patient polyneuropathi
similar entri criteria patisiran apollo studi compani plan
initi addit helios-b studi hereditari wtattr amyloidosi
cardiomyopathi patient late vutrisiran grant orphan drug
design us eu
givosiran acut hepat porphyria givosiran rnai-bas
therapeut util alni esc-galnac conjug technolog
develop treatment acut hepat porphyria ahp administ
once-monthli via subcutan inject target liver express
aminolevulin acid ala synthas ala goal reduc
neurotox heme intermedi ala primari neurotox intermedi
pbg respons caus attack on-going symptom ahp
patient open-label extens data show reduct ala
month result reduct annual attack rate interim
data on-going envis studi demonstr statist
signific lower urinari ala compar placebo patient
month dose givosiran grant orphan drug design
breakthrough therapi design fda well orphan
medicin product design prime design ema
lumasiran primari hyperoxaluria type lumasiran rnai
therapeut target glycol oxidas go therapi util alni
esc-galnac conjug technolog develop treatment
primari hyperoxaluria type ultra-orphan diseas urinari
oxal combin calcium accumul calcium oxal crystal
kidney often progress end-stag renal diseas requir hepato-ren
transplant target glycol oxidas lumasiran work deplet
substrat necessari oxal product show mean
reduct urinari oxal accept safeti profil pivot trial
illuminate-a on-going lumasiran grant orphan drug
design breakthrough therapi design fda well
orphan medicin product design prime design ema
antitrypsin deficiency-associ liver diseas
rnai therapeut target antitrypsin
develop treatment deficiency-associ liver diseas
liver diseas therapi make use alni next gen esc
page analyst certif import disclosur
galnac-conjug technolog cta approv expect trial
aln-lec amyloidosi amyloidosi form
amyloidosi caus deposit non-solubl fibril tissu
individu increas protein product and/or decreas
catabol associ homozyg mutat clinic
featur includ chronic kidney diseas lead renal failur possibl
involv organ aln-lec preclin drug candid
demonstr potent durabl knockdown liver-secret
singl dose month initi natur histori studi
measur progress renal diseas patient
aln-agt hypertens aln-agt rnai therapeut preclin
candid hypertens aln-agt design target angiotensin
shown decreas blood pressur spontan hypertens rat
model aln-agt esc molecul current test nhp
thromboprophylaxi preclin rnai candid show
prevent thrombosi rodent nhp ind readi
cemdisiran iga nephropathi cemdisiran rnai therapeut
util alni esc-galnac conjug technolog target
compliment pathway compani plan investig therapi
trial iga nephropathi
aln-app hereditari cerebr amyloid angiopathi hcaa aim
emul onpattro success hattr-pn indic new rnai
investig candid hcaa caus mutat amyloid
precursor protein app lead amyloid deposit certain area
brain blood vessel associ intracerebr hemorrhag
dementia preclin develop on-going expect molecul
enter clinic
fitusiran hemophilia partner sni fitusiran rnai
therapeut util alni esc-galnac conjug technolog
administ monthli via subcutan inject target antithrombin
goal allow enough thrombin gener prevent bleed
develop treatment hemophilia data
hemophilia patient without inhibitor show reduct
antithrombin baselin reduct result normal thrombin
level sni respons global develop commerci
current enrol patient sever studi hemophilia
patient without inhibitor atlas-inh atlas-a/b atlas-ppx
success elig receiv royalti global net sale
page analyst certif import disclosur
inform hemophilia current treatment competit
landscap see hemophilia background
inclisiran hypercholesterolemia partner mdco inclisiran
rnai therapeut target proprotein convertas subtilisin kexin type
treatment hypercholesterolemia administ
reduct ldl-c dose stat sig vs placebo rel
well toler mdco respons develop commerci
current conduct sever studi cvot studi
evalu drug potenti
lower ldl-c subject high risk atherosclerot cardiovascular diseas
ascvd includ establish ascvd famili hypercholesterolemia
ultim success elig receiv tier royalti rang
low high-teen percentag ww net sale
previous chronic hepat viru infect
partner rnai base therapeut
target hbv protein goal restor abil patient
immun system control infect specif target highli conserv
sequenc viru demonstr multi-log reduct circul
hbsag level murin hbv model singl subcutan inject
phase trial on-going fund cost retain
product-by-product option opt profit-shar arrang follow
aln-hsd non-alcohol steatohepat nash aln-hsd possibl
drug candid treatment nash develop partnership
alni research suggest silenc could lead clinic
benefit select possibl develop candid on-going
expect ind
guggenheim secur llc compani report
within proprietari pipelin onpattro launch updat continu
focu throughout us compani launch
addit geographi anticip approv japan mid-year earli
like march per manag anticip top-line data
givosiran envis trial intend complet nda submiss
page analyst certif import disclosur
ticker drug diseas eventexpect timingpric impact potenti givosiranacut hepat porphyriasenvis phase top-line result givosiranacut hepat porphyriasnda mdco inclisiranhypercholesterolemiaresult orion phase data snyfitusiranhemophiliaresult phase atla hbv infectionphas top-line lumasiranprimari hyperoxaluria type phase top-line result mdco inclisiranhypercholesterolemianda file
mid-year seek full approv well submit top-line
result lumasiran trial illuminate-a expect late
safeti pd data singl ascend dose expect
aln-agt expect evalu clinic trial
partner program mdco expect announc top line data
inclisiran orion studi could also get initi data
fitusiran atla program year top-line data
phase trial expect next year
sni initi enter collabor agreement
compani enter new collabor discov develop
commerci rnai therapeut treat orphan diseas
agreement retain full right alnylam territori sanofi obtain
exclus right sanofi genzym territori januari
compani modifi agreement enter exclus ttr
licens licens term new agreement compani
agre termin co-develop co-commerci right relat
revusiran vutrisiran fitusiran receiv exclus right pursu
global develop commerci ttr product includ
patisiran vutrisiran back-up sni receiv exclus right
pursu global develop commerci fitusiran
back-up sanofi elig receiv royalti onpattro
territori unit state canada western europ
japan sni also elig receiv royalti global sale
vutrisiran elig receiv royalti global net sale
sni still right opt futur rare genet diseas program sni
genzym territori origin collabor one right
global licens subject extens
mdco enter licens collabor agreement
agreement mdco paid up-front exclus
world-wide licens develop manufactur commerci rnai
therapeut target includ inclisiran elig receiv
total mileston next potenti approv
well low- high-teen royalti global net sale
manufactur servic agreement agil
technolog inc provid commerci suppli onpattro initi
five-year term may seek addit special cmo scale-up
page analyst certif import disclosur
futur addit relationship also construct cgmp
manufactur facil norton massachusett develop sirna sirna
conjug lnp conjug clinic commerci use
issu activ mani pend patent applic
us eu japan along countri throughout world
broad portfolio cover oligonucleotid includ modifi unmodifi
synthet rna molecul optim varieti deliveri modal
galnac system synthesi use includ use therapeut
diagnost research reagent patent summar
carnegi institut
double-strand rna induc rnai
non-exclus right therapeut
medic colleg georgia
method inhibit gene express use double-
small double-strand rna therapeut product
medica inhibit express target gene
medica treat tumor diseas
method inhibit express wide varieti
oncolog target gene double-strand rna
nucleotid
composit method inhibit target nucleic
acid double-strand rna base
pair wherein least one end blunt
composit method inhibit target nucleic
acid double-strand rna
rnai use mammalian oocyt preimplant
embryo somat cell ep wherein rnai
compound least base pair
exclus right therapeut
massachusett institut
biomed research
gesellschaft univers
mediat rnai small rna base pair long
claim direct composit method use
manufactur
massachusett institut
institut univers
synthet chemic modifi sirna therapeut
product includ patent claim includ
direct double-strand rna
nucleotid without overhang
claim direct double-strand rna
nucleotid overhang claim direct
double-strand rna base pair
base pair least one nucleotid analogu along
exclus right therapeut
exclus right therapeut
page analyst certif import disclosur
method use make double-strand
method inhibit target nucleic acid via
introduct vector encod double-strand rna
rnai use vivo mammalian liver
exclus right therapeut
claim direct carbohydr conjug link
claim direct galnac-conjug sirna
claim direct highli chemic modifi
oligonucleotid grant claim direct double-
strand rna nucleotid
variou combin chemic modif
also distinct agreement lead pharmaceut
research compani safeguard ip use
regist trademark us eu japan countri copyright
price target per share base dcf analysi
includ current busi well probabl weight pipelin
revenu assum discount rate termin growth
guggenheim secur llc estim mm except per share data
page analyst certif import disclosur
dcf summaryweight averag present valu free cash termin growth rate valu termin p/w equiti valu per
suscept risk appli entir biotech industri
includ develop regulatori commerci manufactur financ
ip risk specif includ
clinic risk concentr effort pioneer rnai
therapeut howev accept risk scientif evid
support feasibl therapi still limit face skeptic
base so-cal off-target effect activ interferon respons
drug candid demonstr efficaci laboratori set may
translat well human clinic trial octob discontinu
develop revusiran investig rnai drug hattr-cm
treatment due safeti concern notabl unexpect safeti issu
may aris lead program could readthrough entir
regulatori risk even develop stage candid clinic trial
ultim success possibl alni medicin approv
global regulatori agenc given novelti rnai technolog
human use agenc may requir addit long-term data could
commerci risk limit experi commerci compani
onpattro first commerci product given natur diseas
possibl may challeng identifi patient gain
market share rel competitor run commerci risk
encount uncertainti commercializing/distribut onpattro drug
competitor risk develop therapi area treatment
option limit possibl risk/benefit alni therapi
may favor effect intens competit pharmaceut
market also antisens oligonucleotide/gen therapy/gen edit
compani develop potenti competit medicin possibl
therapi could prove better safeti efficaci
captur larger market share
dr john maraganor phd chief execut offic dr maraganor
ceo director previous senior vice-president strateg
product develop millennium pharmaceut inc fulli own
subsidiari tkphf serv gener manag millennium
inc former subsidiari millennium role
director molecular biolog director market busi
develop
barri green presid mr green join
previous gener manag oncolog millennium pharmaceut inc
prior mr green serv execut vice-president
chief busi offic mediconsult com vice-president market consum
servic azncf vice-president strateg integr andersen
page analyst certif import disclosur
consult current also serv board
greenstreet serv execut vice-president sinc
prior role dr greenstreet senior vice-president head medicin
develop senior vice-president chief strategi research
develop gsk current also serv scientif advisori
committe melinda gate foundat
dr pushkal garg md chief medic offic dr garg join
vice-president global clinic research immunosci
previous preced dr garg held variou role millennium
pharmaceut also serv member board director sqz
dr saraswathi nochur phd senior vice presid chief
regulatori offic dr nochur join vice-president regulatori
affair program leader two late-stag program prior
dr nochur vice-president regulatori affair mdco director
product develop regulatori affair ceremedix inc earli
director new product develop dynagen inc held
senior posit biotrack inc
dr akshay vaishnaw md phd presid research develop
dr vaishnaw join senior director
translat medicin fellow royal colleg physician uk
member scientif advisori board scholar member
board director visterra inc
manmeet soni ca chief financi offic mr soni join
previous cfo treasur inc
acquir tkphf pharmacycl inc acquir
prior role work zeltiq aesthet inc subsidiari
life scienc pwc san jose pwc
india current board member audit committe chair
page analyst certif import disclosur
initi coverag share neutral rate
proven forc reckon orphan drug space
see valu base busi compani experience/cap
expect continu growth exist commerci portfolio model
sale vs con side compani also
sever iron fire though think near-term option price
point struggl see could surpris upsid
expect posit factor data valrox expect compani
pursu acceler file that larg line consensu
think competit updat could potenti repres headwind
vosoritid data could also catalyst though there
competit overhang question market opportun think
could limit upsid near term compani plenti cash
though arent expect signific would meaning
chang thesi
share mn
factset price
price perform versu nbi
factset price
page analyst certif import disclosur
initi coverag
neutral
orphan diseas compani singular focu
develop therapi patient rare diseas remind rare
diseas defin condit affect fewer us
less eu develop rare diseas therapeut
come legisl defin benefit includ regulatori flexibl
market exclus consequ often higher price limit competit
beyond benefit orphan major bmrn product also
complex biolog molecul provid addit barrier entry/competit
bmrn current market product revenu
potenti estim like continu fuel growth pipelin
advanc compani legaci commerci portfolio consist
naglazym mp vi vimizim mp iv product alon
model revenu
palynziq pku compani newest launch though cautiou
market opportun daili subq product palynziq
approv us may approv eu expect
data show drug clearli effect cautiou
ultim potenti daili subq inject indic note
call initi launch phase exceed expect
think earli bolu patient like slow beyond continu growth
depend get patient doctor offic agre
daili subq inject trivial task expect uptak
acknowledg compani histori success commerci execut though
regard show launch remain consensu sale
vs consensu
expect compani file acceler approv first gene
therapi product valrox hemophilia line
consensu valoctocogen roxaparvovec base gene therapi
produc encourag though far perfect data treatment
hemophilia trial enrol
intend provid updat program expect
compani pursu acceler file strategi base fviii express
line consensu model launch commerci opportun
hemophilia gene therapi remain key question think prospect
cure extend factor replac holiday would valuabl
patient model earli uptak clear argu everi
hemophilia patient want gene therapi think group
patient find risk/benefit gen product accept
also think valrox best posit point vector robust factor
express potenti dose option though note field flux
posit updat competitor could quickli shift expect
compani alreadi leverag gene therapi knowledg
manufactur addit program expect continu
go forward built fulli integr in-hous gene therapi
manufactur capabl think key competit advantag
page analyst certif import disclosur
space facil support multipl bioreactor multipl product
line allow rel uniqu abil effici build
gene therapi pipelin compani next gene therapi product
pku expect enter clinic sever
undisclos gene therapi program work
data studi vosoritid achondroplasia dwarfism bring
anoth pivot catalyst vosoritid modifi recombin c-type
natriuret peptid work increas rate skelet growth
current evalu studi last patient enrol
expect report top-lin data phase data show
treatment pivot g/kg/day dose result increas
annual mean growth veloc vs baselin importantli increas growth
rate led improv proportion key question
program think bode well data endpoint
expect posit updat potenti launch
updat earlier stage clinic pipelin could also come
though arent like valu inflect view tralesinidas alfa
previous bmn enzym replac therapi mpsiiib
leverag icv administr rout use brineura initi data
encourag intend discuss potenti regulatori path
forward fda though timelin conversation/subsequ updat
havent provid also move new program bmn
friedreich ataxia clinic
biomarin commerci pipelin current consist six rare diseas therapeut
guggenheim secur llc compani report
compani also robust pipelin develop stage product
develop treatment rare diseas includ biolog gene
page analyst certif import disclosur
preclinicalphas vivimizimmp ivapalynziqpkucommercialproductstageindicationfda approv april approv april approv decemb approv decemb approv may approv februari approv may
guggenheim secur llc compani report
valoctocogen roxaparvovec hemophilia valoctocogen
roxaparvovec valrox formerli bmn deliv via
treatment hemophilia pivot trial
enrol evalu vg/kg vg/kg dose respect
expect get updat around also announc whether
pursu acceler approv otherwis data need support full
approv expect also conduct phase studi
patient pre-exist antibodi evalu seropreval
peopl sever hemophilia studi determin baselin
characterist peopl hemophilia valrox grant
breakthrough therapi orphan drug design fda prime
orphan drug design ema
palynziq phenylketonuria palynziq enzym substitut therapi
inject subcutan daili treatment phenylketonuria pku
palynziq approv us may current review
europ provid updat market author
applic palynziq grant orphan drug design
fda ema
vosoritid achondroplasia vosoritid modifi recombin c-type
natriuret peptid design spur bone growth children base
pathway enrol patient studi expect report
top-lin data vosoritid grant orphan drug design
fda ema
tralesinidas alfa mp iiib tralesinidas alfa previous bmn
enzym replac therapi deliv fusion recombin human alpha-
n-acetyglucosaminidas naglu peptid deriv insulin-lik
growth factor weekli intracerebroventricular cv infus
studi on-going tralesinidas alfa grant orphan drug
design fda ema
page analyst certif import disclosur
preclinicalphas ahemophilia inhibitorsvosoritideachondroplasiatralesinidas alfamp iiibbmn ataxiabmn roxaparvovecreg data expect enrol expect complet expect xxxxfile ind ind decis enrol
pipelin also investig bmn friedreich ataxia
expect file ind bmn gene therapi
pku deliv phenylalanin hydroxylas pah compani complet
nhp studi plan non-clin studi complet
plan file ind
sever import catalyst expect complet
enrol valrox studi acceler
approv decis studi expect fulli enrol
quarter later pku ema decis palynziq expect
tralesinidas alfa mp iiib plan meet fda regard
potenti acceler approv remain on-going
achondroplasia vosoritid phase top-lin data expect
clinic program trial initi includ bmn friedrich ataxia
pku
guggenheim secur llc compani report
collabor licens agreement
biomarin sarepta enter settlement agreement juli
resolv world-wide patent proceed relat exon-skip treatment
duchenn muscular dystrophi dmd grant sarepta global
exclus right dmd patent estat exondi futur exon-
skip product treatment dmd exchang receiv
elig receiv regulatori commerci mileston fee
receiv royalti net sale end
net sale eu countri patent coverag sep
page analyst certif import disclosur
drug diseas eventexpect timingpric impact potenti valroxhemophilia complet ataxiafil ind valroxhemophilia apotenti top-lin data valroxhemophilia adecis regulatori strategi ind complet top-lin tralesinidas alfamp iiibphas ataxipreclin biotechnolog
biomarin complet sale talazoparib sold brand talzenna
mediv oct mediv acquir pfizer sep
oblig pay mileston payment mid-
singl digit percentag royalti net sale talazoparib
biomarin issu patent world-wide applic pend
includ issu us patent pend us applic
patent
composit method use
method produc purifi
method detect
formul form drug
substanc method use
variou indic regimen
tabl oral solut method
composit method use
method purifi
composit method use
product formul
method treat morquio syndrom
method product
biomarin suit cgmp manufactur facil novato california
protein therapeut dedic gene therapi facil compani also
biolog manufactur facil shanbal cork ireland
capac biolog product
gene therapi facil fulli integr in-hous util
suspens product process largest scale current use gmp
product gene therapi facil support multipl bioreactor
patient per year highest valrox dose potenti
improv effici facil support multipl product line valrox
phase studi bmn clinic studi made commerci
page analyst certif import disclosur
fair valu per share base dcf analysi
forecast probability-weight revenu expens assum
discount rate termin growth rate
guggenheim secur llc estim mm except per share data
suscept risk appli entir biotech industri
includ develop regulatori commerci manufactur financ
ip risk specif includ
commerci risk downsid risk medicin target diseas small
patient popul possibl compani may fail introduc new
product market current product could produc less revenu
expect patient identif may slower expect product may
receiv unfavor payor reimburs upsid risk possibl
market share assumpt conserv preval bmrn
target diseas could prove larger current model
clinic risk downsid risk sever key pipelin product still clinic
develop may delay clinic trial initi enrol
unexpect safeti issu efficaci lower expect upsid
risk upcom data pivot data could prove efficaci
look earlier stage studi also possibl data competitor
could look wors expect unexpect safeti issu could emerg
could benefit bmrn competit posit
regulatori risk downsid risk clinic trial ultim success
possibl bmrn medicin approv global regulatori
agenc given novelti certain medicin develop regulatori
agenc may requir addit long-term data could delay
potenti approv upsid risk hand regulatori process could
go faster smoothli expect
page analyst certif import disclosur
dcf summari weight averag present valu free cash termin growth rate valu termin p/w impli equiti valu per
ip risk downsid risk depend intellectu properti protect
control trade secret technolog innov inabl defend
patent could result increas gener competit addit
compani may accus infring ip upsid risk compani could
defend ip prevail legal proceed
jean-jacqu bienaim chairman chief execut offic mr
bienaim join biomarin chief execut offic member
board director previous chairman ceo
novemb april chairman ceo sangstat medic
corpor late mr bienaim also held sever senior
manag posit rhne-poulenc rorer sanofi-
aventi recent svp world-wide market busi
develop mr bienaim receiv wharton school
univers pennsylvania degre econom cole
dr henri fuch execut vice presid research
develop chief scientif offic dr fuch join biomarin march
prior role chief scientif offic serv chief medic
offic march octob prior join dr fuch
serv evp sep dec
ceo jan jun
dr fuch held variou posit genentech led
clinic program result approv pulmozym respons
phase develop program led approv herceptin
treat metastat breast cancer dr fuch receiv degre georg
washington univers degre biochem scienc harvard
daniel spiegelman execut vice presid chief offic
mr spiegelman join biomarin may previous svp cfo
cv held variou role genentech
may may mr spiegelman also serv
consult portfolio public privat life scienc compani
receiv stanford univers stanford
graduat school busi
jeff ajer execut vice presid chief commerci offic mr ajer
join august prior assum role svp
oct jan vice-president commerci oper
america apr oct prior join mr ajer serv
variou role genzym recent vice presid global transplant
oper dec aug mr ajer receiv
chemistri univers california irvin
oper dr baffi join biomarin may respons
overse manufactur process develop qualiti analyt
page analyst certif import disclosur
chemistri depart prior join serv number
posit genentech primarili function area qualiti control dr
baffi contribut regulatori submiss product
approv unit state europ regulatori
submiss investig new drug test may dr baffi
receiv ph phil biochemistri citi univers
new york regi univers
page analyst certif import disclosur
initi coverag share buy rate
price target think share well posit head given
on-going galafold launch robust pipelin new gene therapi
asset produc sever updat throughout year galafold
think compani commerci execut encourag expect
trend continu us launch continu pipelin
particularli focus new gene therapi program think
clinic preclin updat year import de-
risking/inflect event earli stage program emerg valu driver
factset price
share mn
price perform vs nbi
factset price
page analyst certif import disclosur
initi coverag
buy rate
amicu wholli own pipelin made innov therapi
commerci pre-commerci treatment rare metabol
disord latest stage product/candid deriv fold
chart technolog develop pharmacolog chaperon
target small molecul design bind stabil therapeut
protein restore/optim function compani also leverag
expertis protein fold enzym lysosom storag disord
set gene therapi
fold first commerci product galafold oral chaperon therapi
approv treatment subset fabri diseas galafold
design bind stabil alpha-galactosidas aga enzym
dysfunct fabri patient unlik enzym replac therapi ert
aim replac miss enzym galafold work help exist enzym
patient amen mutat determin fold proprietari
vitro assay drug first approv eu may receiv
acceler approv us august launch gone well far
compani reach market share amen patient
first month us surpass intern expect
compani track hit high end guidanc
model peak galafold sale though see potenti upsid
driven grow awareness/increas diagnosi estim
diagnos fabri patient ww
amen mutat would elig treatment galafold
compani initi uptak driven diagnos patient
switch ert galafold growth driven penetr
diagnos untreat popul think oral therapi
particularli well suit beyond penetr current undiagnos
patient repres long-term opportun fabri diseas tradit
thought affect male though recent studi shown
incid note newli diagnos
patient tend higher rate amen mutat patient
classifi amen could also increas time gener
also develop at-gaa chaperone/ert combo
treatment pomp addit data help character
clinic profil novel ert therapi
chaperon stabil novel enzym combin product
current evalu clinic studi initi result suggest
improv safeti efficaci profil vs exist ert therapi well
get data ert-switch patient cohort data
fold natur histori studi contemporari er treat patient
updat import put uncontrol data context help
de-risk program enter trial inform
pomp competit landscap see pomp background
fold recent deal celenex add gene therapi program
pipelin program focus neurolog lysosom storag
disord make use intrathec deliveri aav preclin poc
page analyst certif import disclosur
alreadi shown program one alreadi clinic
anoth begin trial year end former patient
alreadi treat initi data sibl patient show
meaning impact diseas cours durabl year two-year
data addit patient present also expect
provid updat regulatori strategi year first patient
program treat assum posit progress
first two see potenti compani bring addit program
forward rapidli togeth program could address
patient us eu japan
compani also recent announc collabor upenn work
addit gene therapi program upenn collabor
dr jim wilson amicu work develop gene therapi better
target express secret goal optim safeti
dr wilson novel vector target muscl dna
construct fabri pomp develop area alreadi dr
wilson lab advanc
fold sept cash posit compani well
continu execut pipelin believ current cash posit
suffici least
page analyst certif import disclosur
galafold fabri diseas galafold migalastat oral therapi approv
treatment fabri diseas patient genet mutat
shown respons amen treatment fabri diseas patient suffer
accumul globotriaosylceramid blood vessel kidney
heart nerv vital organ due mutat impact function
alpha-galactosidase-a enzym galafold pharmacolog chaperon
bind misfold enzym render function
at-gaa pomp diseas at-gaa chaperone-advanc enzym
replac therapi treatment pomp diseas made
fold novel ert call co-administ chaperon
combin therapi replac miss non-funct acid alpha-
glucosidas gaa enzym at-gaa current evalu propel
phase clinic trial evalu efficaci late-onset pomp patient
comparison standard-of-car ert therapi sni lumizyme/myozym
recent ad new clinic new preclin gene therapi
program pipelin via acquisit celenex privat spin
nationwid children hospit ohio lead program
batten diseas program util intrathec deliveri aav
trial on-going addit program move
clinic
addit enter collabor dr jame wilson lab
upenn develop gene therapi program treatment pomp diseas
fabri diseas defici one addit undisclos rare metabol
guggenheim secur llc compani report
galafold launch updat continu focu pomp
pivot trial at-gaa pomp propel expect initi
addit expect data ert-switch patient
cohort phase studi
page analyst certif import disclosur
ticker drug diseas eventexpect timingpric impact potenti foldat-gaa pomp diseasedata stride natur histori batten diseasecomplet studi complet batten efficaci data diseasecohort ert switch data foldgen therapyneurolog lsdsaddit preclin poc time clariti foldgalafold fabri diseas updat open-label studi pt foldgalafold fabri diseas long term efficacy/safeti updat
gene therapi studi complet soon addit
data expect studi expect initi dose
full enrol initi cohort expect
collabor partnership
expand gene therapi portfolio partner gene therapi
program perelman school medicin upenn research
collabor licens agreement pursu research develop
new gene therapi pomp diseas fabri diseas defici
one undisclos rare metabol disord agreement upenn
elig receiv certain mileston million/ind royalti
payment base net sale licens product-by-product country-by-
countri respect licens product indic
partnership compani aim combin protein engin
glycobiolog expertis penn aav gene transfer technolog develop
novel aav gene therapi optim cellular uptak target dose safeti
manufactur
obtain global right develop commerci galafold migalastat
monotherapi combin ert fabri diseas gsk
revis agreement novemb receiv
milestones/royalti would provid gsk up-front payment
migalastat monotherapi gsk elig receiv post-approv sales-
base mileston million tier royalti mid-teen
major market outsid us
exclus world-wide right develop commerci galafold
pharmacolog chaperon prevention/treat human
diseas pursuant licens agreement mount sinai school medicin
mssm new york univers own right ip relat ten
gene therapi program acquir celenex detail summari
compani ip posit
patent scope patent subject potenti extens
patent expiri us
patent expiri eu
exclus licens issu us patent cover use
migalastat treat fabri diseas method treatment method
increas activ prevent degrad alpha-gal-a
composit matter patent
expir
page analyst certif import disclosur
us issu patent cover dose regimen migalastat
us issu patent cover synthet step commerci
process migalastat prepar
jointli us eu hkg mex patent cover method
determin likelihood male fabri pt treatment
us issu patent cover method treat fabri pt
one sever alpha-g mutat migalastat
pend us applic cover method determin
amen alpha-g mutat would respons
patent issu
issu patent chn
 exclus licens pend patent applic cover co-
administr migalastat ert patent cover specif
combin issu us eu chn ind isr
 patent
 applic famili pend countri
us patent cover specif dose dose regimen
migalastat treat fabri ert foreign counterpart
applic row countri
at-gaa pomp
us patent applic cover co-formul rhgaa
patent issu foreign counterpart
patent pend
twn
patent applic seri cover reagent method coupl
target peptid rhlysosom enzym patent issu
us eu pend us eu jpn bra chn kor
issu
depend
issu
depend specif
patent applic cover modifi gaa bind
effect receptor potent convent
recombin enzym pend us au bra chn
eurasia eu isr ind jpn kor mex sgp twn zaf
exclus ww licens certain patent right held univers
bologna includ issu us patent pend us
patent applic direct novel fusion protein
issu
issu
issu
issu
acquir right relat ip gene therapi program
price target per share base sum-of-the-part
peak revenu analysi appli multipl product global peak
sale assum discount rate sum-of-the-part basi
arriv galafold fabri diseas commerci at-gaa
pomp diseas po rest valuat come
pipelin platform cash
page analyst certif import disclosur
suscept risk appli entir biotech industri
includ develop regulatori commerci manufactur financ
ip risk specif includ
clinic risk possibl could experi regulatori
delay slower expect clinic trial neg data develop
program addit unexpect safeti issu could emerg particularli
gene therapi program readthrough broader pipelin
regulatori risk clinic trial ultim success possibl
fold medicin approv global regulatori agenc galafold
current acceler approv us possibl compani
success gener data convert full approv given
novelti gene therapi technolog agenc may requir addit
long-term data could delay potenti approv
ip risk ip use galafold treat fabri diseas monotherapi
expir us expir europ japan
right patent possibl robust gene therapi
aav vector-gen therapi landscap rapidli evolv
guarante access new develop technolog
emerg space
manufactur risk manufactur complex biolog viral vector gene
therapi complic expens possibl could encount
stumbl block along way particularli gene therapi program
compani work translat academ program larger scale
headlin risk aav vector-gen therapi technolog wide follow
public media possibl news technolog
unrel could lead either upsid downsid share
page analyst certif import disclosur
john crowley chairman ceo mr crowley chairman
sinc ceo prior join found
orexq co-found novazym pharmaceut inc latter
acquir genzym corpor mr crowley serv senior vice-president
genzym sni novazym mr crowley serv sever
senior manag role addit commiss offic
us navi reserv assign us special oper command
veteran serv afghanistan henri crown fellow
aspen institut nation chairman make wish foundat
america found board member global gene project
bradley campbel presid chief oper offic mr campbel
presid member board director
join serv variou commerci busi
develop role genzym strategi consult
marakon associ also serv member board director
bionj board corpor advisori board nation tay-sach
dr jay barth md chief medic offic dr barth join
prior held role
recent role senior vice-president clinic develop previous also
serv execut director clinic research vice-president clinic
research medic affair altana pharma us inc senior
director global head gastroenterolog clinic research esalf
current cpo previous healthcar strategi
consult health advanc llc work busi develop
baird chief offic mr baird join
cfo previous serv cfo work consult
corpor underwrit first union nation bank current also
serv director
page analyst certif import disclosur
resum coverag share buy rate
price target like head manag uncertainti
move rearview mirror think base busi posit
well taf launch prep tailwind predict hcv top
compani sever data readout next year selonsertib
coin-flip view though work increas confid head
arguabl import combin data believ filgotinib
data like posit though acknowledg regulatory/market qs
limit enthusiasm posit pivot data never hurt
share mn
factset price
price perform versu nbi
factset price
page analyst certif import disclosur
resum coverag
buy rate
price target
trough year think averag thing look
 announc new ceo behind us focu
meaning fundament think daniel oday strong
commerci background plu knowledg oncolog
immunolog space area work build presenc
 taf launch gone realli well expect
continu fact biktarvi becom regimen treatment
nave switch patient us full quarter launch
impress highlight level physician patient
comfort confid gild regimen think bode well
durabl gild hiv revenu face new competit
 think prep appreci momentum
build repres small hiv sale think growth
continu underestim street model truvada sale
hold steadi patent expiri vs consensu
 sever shot goal nash took deep dive
selonsertib data think upcom readout coin flip
though expect low risk/reward skew upsid
combo therapi front atla combin studi complet
enrol novemb note interim analysi
week could enabl rapid move detail
nash competit landscap see nash background
 hcv fine declin predict way predict good
 rest filgotinib trial like posit base
data success outcom finch expect
data releas major stock mover share quickli gave
back got finch headlin vs flat nbi slow roll
posit news cant hurt said troubl get excit
filgotinib given regulatori preced success
signific invest launch
 exact grow gener
cash flow option part thesi isnt new
hasnt play last sever year focu
investor think recent manag turnov probabl mean
meaning horizon said option still
lot cash
page analyst certif import disclosur
gilead pipelin focus four main categori hiv liver diseas
inflammation/respiratori hematology/oncolog
page analyst certif import disclosur
guggenheim secur llc compani report
page analyst certif import disclosur
phase agonisthivhiv inhibitornashrheumatoid arthritiscrohn diseaseulc colitispsoriat arthritisinflammatori diseasesulc colitistesticular safeti studypresatovirfus inhibitorrsvsjogren inhibitorinflammatori bowel diseaseindol mab dlbclr/r larg b-cell combomcladult allpediatr solid solid tumorsentospletinibsyk inhibitorhem malignanciestirabrutinibbtk inhibitorb-cel malignanciestango partnershiptbaremdesivirnuc inhibitorotherebola viru infectionhematolog oncologyindicationliv diseasesinflamm inhibitoryescarta axicabtagen data expect combin studi enrol data stellar data expect atla combin studi finch data complet enrol enrol complet enrol expect complet enrol expect top-lin expect reportedatla combin studi complet complet enrol expect data expect data expect enrol first endpoint ind
descovi pre-exposur prophylaxi descovi combin
emtricitabin ftc tenofovir alafenamid taf drug alreadi
approv treatment infect phase studi discov
on-going men transgend men use pre-exposur prophylaxi
prep gilead expect report top-lin data
hiv/aid gilead sever program pipelin treatment cure
hiv/aid oral nucleotid revers transcriptas inhibitor aim
patient highli resist nucleosid ftc
product like descovi truvada phase studi
compani expect report top-lin data hiv capsid
inhibitor shown long-act potenti month subcutan
inject dose schedul evalu phase studi
hiv cure vesatolimid prev toll-lik receptor agonist
phase studi broadli neutral antibodi bnab
target hiv envelop gilead plan conduct dose-rang phase
studi follow dose-rang studi compound gilead plan
nash pipelin selonsertib first-in-class apoptosi signal-regul
kinas inhibitor develop treatment nash drug
aim inflamm fibrosi pathway nash current
evalu selonsertib two phase trial stellar stellar
studi complet enrol april manag expect report
top-lin data respect
acetyl-coa carboxylas inhibitor target fibrosi
pathway nash octob report data random
placebo-control phase studi evalu patient stage
fibrosi non-steroid farnesoid receptor fxr agonist intend
modul steatosi evalu phase trial
evalu patient fibrosi well part phase atla
combin studi also evalu phase studi pbc
psc
evalu selonsertib phase
atla combin monotherapi studi trial fulli enrol
expect report data combin studi
hepat viru hbv aim function cure
chronic hepat viru hbv current evalu multipl
filgotinib filgotinib inhibitor develop collabor
galapago glpg inflammatori condit phase develop
rheumatoid arthriti ra ulcer coliti uc crohn diseas cd
page analyst certif import disclosur
